MGI Tech Co., Ltd., a leader in life science innovation, has established a strategic partnership with Oncoclínicas&Co, a prominent Brazilian oncology group. This collaboration aims to enhance access to advanced genomic testing and bolster diagnostic capabilities in Brazil’s oncology sector.
The partnership focuses on integrating cutting-edge genomic technologies to improve early cancer detection and treatment efficacy. Carlos Carpio, Senior Commercial Director for MGI Latin America and General Manager for Brazil, emphasized the significance of this collaboration, stating, “Genomics is transforming the way we understand and treat cancer, and this partnership is a major milestone for oncology in Brazil because it helps raise awareness among patients and professionals about the positive impact of oncogenetics on health promotion, possibilities and benefits of a more precise and personalized medicine, to facilitate the access to advanced technologies and to expand genetic diagnostic capacity.”
Also Read: Yemaachi Biotechnology Launches The African Cancer Atlas, in Partnership with Roche
Through this alliance, Oncoclínicas&Co will incorporate MGI‘s DNBSEQ-G400 genomic sequencer, enhancing their diagnostic precision and accelerating the development of personalized cancer treatments. Fernanda Koyama, Manager of Genomics and R&D at Oncoclínicas&Co, noted, “This collaborative approach empowers our laboratory to offer faster, more accurate diagnostic testing, ultimately improving patient outcomes and accelerating the development of personalized treatments.”
This partnership underscores a shared commitment to advancing genomic medicine and improving cancer care in Brazil.